Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.50 |
| ▸ | ITGAL | P20701 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224671 | 0.79 | FBP1 (0.58) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL3165346 | 0.79 | ITGB2 (0.72) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL30472043 | 0.79 | FBP1 (0.58) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL4127172 | 0.77 | ITGB2 (0.52) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL19122057 | 0.76 | CCR2 (0.38) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL866006 | 0.76 | CYP3A4 (0.52) | ITGB2ICAM1ITGALTP53TSHR | |
| SCHEMBL3249437 | 0.76 | PDE7A (0.59) | ITGB2ICAM1ITGALTSHRCYP3A4 | |
| SCHEMBL5044607 | 0.75 | ITGB2 (0.55) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL10834427 | 0.75 | ITGB2 (0.50) | ITGB2ICAM1ITGALTP53IDO1 | |
| SCHEMBL8779862 | 0.75 | ITGB2 (0.50) | ITGB2ICAM1ITGALTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2023-06-08 | — | — | US | disclosed |
| CN-102166403-B | Multilayer core golf ball | ACUSHNET CO | 2015-02-18 | — | — | CN | disclosed |
| US-8834297-B2 | Multi-layer core golf ball | ACUSHNET COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8529374-B2 | Golf ball with negative hardness gardient core | ACUSHNET COMPANY (US) | 2013-09-10 | — | — | US | disclosed |
| US-8382612-B2 | Multi-layer core golf ball | ACUSHNET COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8221266-B2 | Golf ball core with soft outer transition volume and negative hardness gradient | ACUSHNET COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20120149498-A1 | MULTI-LAYER CORE GOLF BALL | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2012-06-14 | — | — | US | disclosed |
| US-20120116001-A1 | GOLF BALL COMPOSITIONS | ACUSHNET COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-20120004051-A1 | GOLF BALL CORE WITH SOFT OUTER TRANSITION VOLUME AND NEGATIVE HARDNESS GRADIENT | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2012-01-05 | — | — | US | disclosed |
| US-20110230280-A1 | GOLF BALL WITH NEGATIVE HARDNESS GARDIENT CORE | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174545-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | ITGB2 4156/4885ICAM1 4287/4885ITGAL 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.